It's inconceivable that an "experience practitioner" can devise a treatment a drug company can't manufacture, but you are correct that the economics of personli

It's inconceivable that an "experience practitioner" can devise a treatment a drug company can't manufacture, but you are correct that the economics of personlised medicines aren't financially viable for drug companies. I don't think there is a simple solution for that, but I can tell you is that these economics still won't prevent the discovery of such treatments. Some initial proof of this is the fact that the scientific community has embraced the concept that cancer is extremely heterogenous and will require a unique treatment for each individual patient (which has generated the "personalised medicine" buzzword).